BMS gets FDA nod for ozanimod, but launch will be delayedBristol-Myers Squibb’s multiple sclerosis therapy ozanimod has been approved by the FDA right on schedule, but the company Share XBMS gets FDA nod for ozanimod, but launch will be delayedhttps://pharmaphorum.com/news/bms-gets-fda-nod-for-ozanimod-but-launch-will-be-delayed/
Celgene scores FDA okay for thalassaemia drug ReblozylThe FDA has approved Celgene and Acceleron’s Reblozyl, which is the first drug to be approved in the Share XCelgene scores FDA okay for thalassaemia drug Reblozylhttps://pharmaphorum.com/news/celgene-scores-fda-okay-for-thalassaemia-drug-reblozyl/
Biogen bags FDA okay for Tecfidera follow-up VumerityBiogen’s multiple sclerosis franchise has been handed a boost with the US approval of Vumerity, a follow-up to Share XBiogen bags FDA okay for Tecfidera follow-up Vumerityhttps://pharmaphorum.com/news/biogen-fda-tecfidera-vumerity-ms/
Merck, Eisai get triple approvals for Keytruda/Lenvima combinationThe combination of Merck & Co’s Keytruda with targeted drug Lenvima has been approved for endometrial cancer in Share XMerck, Eisai get triple approvals for Keytruda/Lenvima combinationhttps://pharmaphorum.com/news/merck-eisai-get-triple-approvals-for-keytruda-lenvima-combination/
J&J gets Stelara okay in Europe for ulcerative colitisJohnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new Share XJ&J gets Stelara okay in Europe for ulcerative colitishttps://pharmaphorum.com/news/jj-gets-stelara-okay-in-europe-for-ulcerative-colitis/
Daiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumourDaiichi Sankyo’s pexidartinib has become the first FDA-approved therapy for tenosynovial giant cell tumour (TGCT), a rare form Share XDaiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumourhttps://pharmaphorum.com/news/daiichi-sankyos-pexidartinib-is-first-fda-approved-drug-for-rare-tumour/
FDA clears Karyopharm’s myeloma drug despite advisory panel rejectionThe FDA has taken the unusual step of over-ruling its own advisory committee and approving Karyopharm’s Xpovio as Share XFDA clears Karyopharm’s myeloma drug despite advisory panel rejectionhttps://pharmaphorum.com/news/fda-clears-karyopharms-myeloma-drug-despite-advisory-panel-rejection/
AMAG bags FDA okay for second ‘female Viagra’ drugAMAG Pharma has won US approval for a new drug to treat decreased libido in premenopausal that will Share XAMAG bags FDA okay for second ‘female Viagra’ drughttps://pharmaphorum.com/news/amag-bags-fda-okay-for-second-female-viagra-drug/
Sanofi, Merck’s Vaxelis is first six-in-one vaccine in USSanofi and Merck & Co picked up late 2018 approval from the FDA during the holiday period, getting Share XSanofi, Merck’s Vaxelis is first six-in-one vaccine in UShttps://pharmaphorum.com/news/sanofi-mercks-vaxelis-is-first-six-in-one-vaccine-in-us/
